AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Hims & Hers Q2 GLP-1 Revenue Falls Short of Expectations.
ByAinvest
Wednesday, Aug 6, 2025 1:03 pm ET1min read
Hims & Hers Health reported Q2 results showing a larger-than-expected hiccup in GLP-1 revenue, causing a -13% drop in the telehealth platform's stock. The company's GLP-1 strategy is on dubious grounds, as the revenue miss was unexpected and the stock market reacted negatively. This may indicate challenges in the company's strategy or execution.
Hims & Hers Health, Inc. (HIMS) reported its second-quarter 2025 earnings on August 4, 2025, revealing a larger-than-expected dip in GLP-1 revenue. This news led to a significant drop in the company's stock, with shares falling by approximately 13% in after-hours trading [1].Despite the revenue miss, the company reported strong growth in core areas. Revenue jumped 73% year-over-year to $544.8 million, but it fell short of Wall Street's expectations of $552 million. The company also delivered adjusted earnings per share (EPS) of 17 cents, beating the 15 cents estimate, and adjusted EBITDA of $82 million, more than doubling from the previous year's $39.3 million [2].
The stock market's negative reaction to the GLP-1 revenue miss suggests growing concerns about the company's strategy and execution in this area. Hims & Hers has faced scrutiny for distributing cheaper, unapproved versions of popular diabetes and weight-loss drugs, including GLP-1 therapies. While the FDA had previously resolved supply issues, some telehealth players, including Hims, continue to offer personalized doses [2].
The company's guidance for the third quarter also fell short of expectations, with EBITDA guidance ($60M-$70M) falling short of StreetAccount's $77.1 million forecast. Hims & Hers will need to convince investors that its fast growth won't be overshadowed by regulatory headwinds [2].
Analysts remain divided on the future of HIMS stock. The average target price for Hims & Hers Health Inc. is $48.49, with a high estimate of $85.00 and a low estimate of $28.00. GuruFocus estimates the company's fair value at $36.01 [2].
Hims & Hers Health faces ongoing challenges in its GLP-1 strategy and execution. The company must address these concerns and provide clear evidence of its long-term growth prospects to regain investor confidence.
References:
[1] https://stockanalysis.com/stocks/hims/
[2] https://www.tradingview.com/news/gurufocus:259e0cac6094b:0-hims-hers-stock-nosedives-after-q2-revenue-miss-despite-73-growth/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet